Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis

References

• Nimer SD. Myelodysplastic syndromes. Blood. 2008;111:4841–51. doi: 10.1182/blood-2007-08-078139
   PubMed Web of Science ®Google Scholar
• Nolte F, Hofmann WK. Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol. 2008;87:777–95. doi: 10.1007/s00277-008-0502-z
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872–85. doi: 10.1056/NEJMra0902908
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–302. doi: 10.1182/blood-2002-04-1199
   PubMed Web of Science ®Google Scholar
• Fisher CL, Berger J, Randazzo F, Brock HWA. Human homolog of additional sex combs, additional sex combs-like 1, maps to chromosome 20q11. Gene. 2003;306:115–26. doi: 10.1016/S0378-1119(03)00430-X
   PubMed Web of Science ®Google Scholar
• Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. Nature. 2010;465:243–7. doi: 10.1038/nature08966
   PubMed Web of Science ®Google Scholar
• Cho YS, Kim EJ, Park UH, Sin HS, Um SJ. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem. 2006;281:17588–98. doi: 10.1074/jbc.M512616200
   PubMed Web of Science ®Google Scholar
• Fisher CL, Randazzo F, Humphries RK, Brock HW. Characterization of Asxl1, a murine homolog of additional sex combs, and analysis of the Asx-like gene family. Gene. 2006;369:109–18. doi: 10.1016/j.gene.2005.10.033
   PubMed Web of Science ®Google Scholar
• Lee SW, Cho YS, Na JM, Park UH, Kang M, Kim EJ, et al. ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem. 2010;285:18–29. doi: 10.1074/jbc.M109.065862
   PubMed Web of Science ®Google Scholar
• Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C, et al. Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood. 2010;115:38–46. doi: 10.1182/blood-2009-07-230698
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145:788–800. doi: 10.1111/j.1365-2141.2009.07697.x
   PubMed Web of Science ®Google Scholar
• Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ, et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia. 2010;24:1062–5. doi: 10.1038/leu.2010.20
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011;25:1200–2. doi: 10.1038/leu.2011.58
   PubMed Web of Science ®Google Scholar
• Pratcorona M, Abbas S, Sanders M, Koenders J, Karelaars F, Erpelinck-Verschueren C, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012;97:388–92. doi: 10.3324/haematol.2011.051532
   PubMed Web of Science ®Google Scholar
• Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010;10:401–7. doi: 10.1186/1471-2407-10-401
   PubMed Web of Science ®Google Scholar
• Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12 and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012;51:743–55. doi: 10.1002/gcc.21960
   PubMed Web of Science ®Google Scholar
• Boultwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R, et al. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia. 2010;24:1139–45. doi: 10.1038/leu.2010.65
   PubMed Web of Science ®Google Scholar
• Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adélaïde J, Rey J, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23:2183–6. doi: 10.1038/leu.2009.141
   PubMed Web of Science ®Google Scholar
• Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comblike 1 (ASXL1) mutations. Blood. 2011;116:4086–94. doi: 10.1182/blood-2010-05-283291
   Web of Science ®Google Scholar
• Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, et al. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and postpolycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica. 2011;96:1462–9. doi: 10.3324/haematol.2011.045591
   PubMed Web of Science ®Google Scholar
• Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118:5593–603. doi: 10.1182/blood-2011-03-343988
   PubMed Web of Science ®Google Scholar
• Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118:3932–41. doi: 10.1182/blood-2010-10-311019
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70:447–52. doi: 10.1158/0008-5472.CAN-09-3783
   PubMed Web of Science ®Google Scholar
• Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adélaïde J, et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia. 2010;24:469–73. doi: 10.1038/leu.2009.218
   PubMed Web of Science ®Google Scholar
• Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia. 2012;25:877–9. doi: 10.1038/leu.2011.10
   Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997;315:629–34. doi: 10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• Chen T-C, Houl H-A, Chou W-C, Tang J-L, Kuo Y-Y, Chen C-Y, et al. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J. 2014;4:e177. doi: 10.1038/bcj.2013.74
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–506. doi: 10.1056/NEJMoa1013343
   PubMed Web of Science ®Google Scholar
• Thol F, Friesen I, Damm F, Yun H, Eva M, Weissinger E, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011;29:2499–506. doi: 10.1200/JCO.2010.33.4938
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151:365–75. doi: 10.1111/j.1365-2141.2010.08381.x
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428–36. doi: 10.1200/JCO.2012.47.3314
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach T, Schnittger S, Zenger M, Meggendorfer M, Jeromin S, et al. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact. Br J Haematol. 2014;164:822–33. doi: 10.1111/bjh.12710
   PubMed Web of Science ®Google Scholar
• Thol F, Winschel C, Lüdeking A, Yun H, Friesen I, Damm F, et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica. 2011;96:1870–3. doi: 10.3324/haematol.2011.045559
   PubMed Web of Science ®Google Scholar
• Wang J, Ai X, Gale RP, Xu Z, Qin T, Fang L, et al. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leuk Res. 2013;37:305–11. doi: 10.1016/j.leukres.2012.10.004
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27:1504–10. doi: 10.1038/leu.2013.88
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34. doi: 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   PubMed Web of Science ®Google Scholar
• Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:3852–9. doi: 10.1200/JCO.2004.02.109
   PubMed Web of Science ®Google Scholar
• Ottawa Hospital Research Institute. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2009. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. doi: 10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101. doi: 10.2307/2533446
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011;25:1200–2. doi: 10.1038/leu.2011.58
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN favorable genetic category. Blood. 2011;118:6920–9. doi: 10.1182/blood-2011-08-368225
   PubMed Web of Science ®Google Scholar
• Shivarov V, Gueorguieva R, Ivanova M, Tiu RV. ASXL1 mutations define a subgroup of AML patients with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult AML patients. Leuk Lymphoma. 2015;56:1881–3. doi: 10.3109/10428194.2014.974596
   PubMed Web of Science ®Google Scholar
• Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood. 2010;116:4086–94. doi: 10.1182/blood-2010-05-283291
   PubMed Web of Science ®Google Scholar
• El-Sharkawi D, Ali A, Evans CM, Hills RK, Burnett AK, Linch DC, et al. ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification. Leuk Lymphoma. 2014;55:1326–31. doi: 10.3109/10428194.2013.833332
   PubMed Web of Science ®Google Scholar
• Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia. 2013;27:82–91. doi: 10.1038/leu.2012.262
   PubMed Web of Science ®Google Scholar